{"paper_id":"2e10d7d5-afba-4114-8dfa-9f63e748b95b","body_text":"Article Text\nAbstract\nEndometrial stromal sarcoma (ESS) is a rare uterine malignancy originating from endometrial connective tissue. It is classified into benign and malignant subtypes. While it primarily affects perimenopausal women aged 45–55 years, younger patients may also be affected. ESS often presents with symptoms such as abnormal uterine bleeding, pelvic pain or pelvic mass, mimicking benign conditions like fibroids. Definitive treatment includes total hysterectomy with bilateral salpingo-oophorectomy, complemented by hormonal therapy for advanced cases.\nDespite its indolent nature, low-grade ESS (LGESS) requires long-term follow-up due to significant recurrence risk. We present a case of a woman in her late 20s, who underwent hysterectomy for severe bleeding and anaemia, with LGESS diagnosed later during a growing abdominal wall mass evaluation.\nImaging and biopsy confirmed her diagnosis. She underwent extensive debulking surgery. Histological analysis revealed oval to spindle cells, low mitotic activity, no necrosis or atypical mitotic figures; Estrogen Receptor (ER), Progesterone Receptor (PR) and CD10 positivity, which were consistent with LGESS.\n- Cancer - see Oncology\n- Gynecological cancer\n- Uterus\nStatistics from Altmetric.com\nFootnotes\nContributors The following authors were responsible for drafting the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content: SP and RK. The following authors gave final approval of the manuscript: JM and BA. RK is the guarantor.\nFunding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.\nCase reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.\nCompeting interests None declared.\nProvenance and peer review Not commissioned; externally peer reviewed.","source_license":"CC0","license_restricted":false}